E-cadherin and p63 immunoexpression in dysplastic lesions and urothelial carcinomas of the bladder

Romanian Journal of Morphology and Embryology

Volumn 50, Issue 3, 2008, Pages 461-465

  Stepan, A ^a   Mǎrgǎritescu, Cl ^a   Simionescu, Cristiana ^a   Ciurea, Raluca ^a  

^a UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

Author keywords

Bladder urothelial carcinoma; E cadherin; P63

Indexed keywords

CADHERIN; TP63 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BLADDER TUMOR; CELL DIFFERENTIATION; HUMAN; METABOLISM; PATHOLOGY;

CADHERINS; CELL DIFFERENTIATION; HUMANS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 70349178114     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. JOHANSSON S. L., COHEN S. M., Epidemiology and etiology of bladder cancer, Semin Surg Oncol, 1997, 13(5):291-298.
2. GREENLEE R. T., HILL-HARMON M. B., MURRAY T., THUN M., Cancer statistics 2001, CA Cancer J Clin, 2001, 51(1):15-36.
3. KNOWLESS M. A., Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?, Carcinogenesis, 2006, 27(3):361-373.
4. BINDELS E. M., VERMEY M., DE BOTH N. J., VAN DER KWAST T. H., Influence of the microenvironment on invasiveness of human bladder carcinoma cell lines, Virchows Arch, 2001, 439(4):552-559.
5. DESAI S., LIM S. D., JIMENEZ R. E., CHUN T., KEANE T. E., MCKENNEY J. K., ZAVALA-POMPA A., COHEN C., YOUNG R. H., AMIN M. B., Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia, Mod Pathol, 2000, 13(12):1315-1323.
6. GARCÍA RODRÍGUEZ J., FERNÁNDEZ GÓMEZ J. M., ESCAF BARMADAH S., GONZÁLEZ ÁLVAREZ R. C., RODRÍGUEZ ROBLES L., MIRANDA ARANZUBIA O., Prognostic factors on recurrence and progression of superficial bladder cancer. Risk groups (Part I), Actas Urol Esp, 2006, 30(10):998-1008.
7. MONTIRONI R., LOPEZ-BELTRAN A., The 2004 WHO classification of bladder tumors: a summary and commentary, Int J Surg Pathol, 2005, 13(2):143-153.
8. LOPEZ-BELTRAN A., SAUTER G., KNOWLES M. A. et al., Tumours of the urinary system. In: EBLE J. N., SAUTER G., EPSTEIN J. I., SESTERHENN I. A. (eds), World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs, IARC Press, Lyon, 2004, 90-157.
9. POPOV Z., GIL-DIEZ DE MEDINA S., LEFRERE-BELDA M. A., HOZNEK A., BASTUJI-GARIN S., ABBOU C. C., THIERY J. P., RADVANYI F., CHOPIN D. K., Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information, Brit J Cancer, 2000, 83(2):209-214.
10. SUN W., HERRERA G. A., E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma, Hum Pathol, 2002, 33(10):996-1000.
11. SUN W., HERRERA G. A., E-cadherin expression in invasive urothelial carcinoma, Ann Diagn Pathol, 2004, 8(1):17-22.
12. CLAIROTTE A., LASCOMBE I., FAUCONNET S., MAUNY F., FÉLIX S., ALGROS M. P., BITTARD H., KANTELIP B., Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors, Am J Clin Pathol, 2006, 125(1):119-126.
13. GARCIA DEL MURO X., TORREGROSA A., MUÑOZ J., CASTELLSAGUÉ X., CONDOM E., VIGUÉS F., ARANCE A., FABRA A., GERMÀ J. R., Prognostic value of the expression of E-cadherin and beta-catenin in bladder cancer, Eur J Cancer, 2000, 36(3):357-362.
14. SYRIGOS K. N., KRAUSZ T., WAXMAN J., PANDHA H., ROWLINSON-BUSZA G., VERNE J., EPENETOS A. A., PIGNATELLI M., E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumour stage and survival, Int J Cancer, 1995, 64(6):367-370.
15. ERDEMIR F., OZCAN F., KILICASLAN I., PARLAKTAS B. S., ULUOCAK N., GOKCE O., The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma, Int Urol Nephrol, 2007, 39(4):1031-1037.
16. COMPÉRAT E., CAMPARO P., HAUS R., CHARTIER-KASTLER E., BART S., DELCOURT A., HOULGATTE A., FRANÇOIS R., CAPRON F., VIEILLEFOND A., Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases, Virchows Arch, 2006, 448(3):319-324.
17. KOGA F., KAWAKAMI S., KUMAGAI J., TAKIZAWA T., ANDO N., ARAI G., KAGEYAMA Y., KIHARA K., Impaired Delta Np63 expression associates with reduced beta-catenin and aggressive phenotypes of urothelial neoplasms, Brit J Cancer, 2003, 88(5):740-747.
18. KOGA F., KAWAKAMI S., FUJII Y., SAITO K., OHTSUKA Y., IWAI A., ANDO N., TAKIZAWA T., KAGEYAMA Y., KIHARA K., Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder, Clin Cancer Res, 2003, 9(15):5501-5507.
19. URIST M. J., DI COMO C. J., LU M. L., CHARYTONOWICZ E., VERBEL D., CRUM C. P., INCE T. A., MCKEON F. D., CORDON-CARDO C., Loss of p63 expression is associated with tumor progression in bladder cancer, Am J Pathol, 2002, 161(4):1199-1206.
20. WESTFALL M. D., PIETENPOL J. A., p63: Molecular complexity in development and cancer, Carcinogenesis, 2004, 25(6):857-864.
21. PELLEGRINI G., DELLAMBRA E., GOLISANO O., MARTINELLI E., FANTOZZI I., BONDANZA S., PONZIN D., MCKEON F., DE LUCA M., p63 identifies keratinocyte stem cells, Proc Natl Acad Sci USA, 2001, 98(6):3156-3161.